TY - JOUR
T1 - Arg389Gly-β1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol
AU - Chen, Lu
AU - Meyers, Deborah
AU - Javorsky, George
AU - Burstow, Darryl
AU - Lolekha, Pakorn
AU - Lucas, Margaret
AU - Semmler, Annalese B.T.
AU - Savarimuthu, Santiyagu M.
AU - Fong, Kwun M.
AU - Yang, Ian A.
AU - Atherton, John
AU - Galbraith, Andrew J.
AU - Parsonage, William A.
AU - Molenaar, Peter
PY - 2007/11
Y1 - 2007/11
N2 - OBJECTIVE: Administration of the β-adrenergic receptor blocker carvedilol to patients with chronic heart failure leads to clinically significant benefits, including improvement in left ventricular systolic function in some, but not all, patients. We sought to determine the basis of the variable effect obtained with carvedilol in patients with heart failure. Carvedilol blocks both β1-adrenergic and β2-adrenergic receptors, and both receptors exist as polymorphisms. We aimed to determine whether these polymorphisms contribute to variability in response to carvedilol in patients with chronic heart failure. METHODS: We retrospectively and prospectively investigated 135 patients with nonischemic cardiomyopathy and chronic stable heart failure (New York Heart Association class II, III) treated with carvedilol. Baseline echocardiography was obtained before introduction of carvedilol and repeated after stabilization of a maximally tolerated dose of carvedilol (50-100 mg/day) for at least 1 year. Polymerase chain reaction and restriction fragment length polymorphism analysis were used to genotype β1-adrenergic and β2-adrenergic receptor polymorphisms. RESULTS: When grouped according to receptor polymorphisms patients were well matched for severity of heart failure, comorbidity and treatment. No significant difference was observed in baseline left ventricular ejection fraction (LVEF) between groups (P>0.05). After 1.5 years of treatment with carvedilol patients with Arg389Arg-β1-adrenergic receptors had a significantly greater improvement in LVEF compared with Gly389 carriers (Arg389Arg 18.8%; Arg389Gly 9.4%; Gly389Gly 6.0%; P<0.001) whereas there were no differences attributable to other β1-adrenergic and β2-adrenergic receptor polymorphisms (P>0.05). CONCLUSION: In patients with nonischemic dilated cardiomyopathy, carvedilol leads to a significantly greater improvement in LVEF in patients with the Arg389Arg-β1 adrenergic receptor phenotype.
AB - OBJECTIVE: Administration of the β-adrenergic receptor blocker carvedilol to patients with chronic heart failure leads to clinically significant benefits, including improvement in left ventricular systolic function in some, but not all, patients. We sought to determine the basis of the variable effect obtained with carvedilol in patients with heart failure. Carvedilol blocks both β1-adrenergic and β2-adrenergic receptors, and both receptors exist as polymorphisms. We aimed to determine whether these polymorphisms contribute to variability in response to carvedilol in patients with chronic heart failure. METHODS: We retrospectively and prospectively investigated 135 patients with nonischemic cardiomyopathy and chronic stable heart failure (New York Heart Association class II, III) treated with carvedilol. Baseline echocardiography was obtained before introduction of carvedilol and repeated after stabilization of a maximally tolerated dose of carvedilol (50-100 mg/day) for at least 1 year. Polymerase chain reaction and restriction fragment length polymorphism analysis were used to genotype β1-adrenergic and β2-adrenergic receptor polymorphisms. RESULTS: When grouped according to receptor polymorphisms patients were well matched for severity of heart failure, comorbidity and treatment. No significant difference was observed in baseline left ventricular ejection fraction (LVEF) between groups (P>0.05). After 1.5 years of treatment with carvedilol patients with Arg389Arg-β1-adrenergic receptors had a significantly greater improvement in LVEF compared with Gly389 carriers (Arg389Arg 18.8%; Arg389Gly 9.4%; Gly389Gly 6.0%; P<0.001) whereas there were no differences attributable to other β1-adrenergic and β2-adrenergic receptor polymorphisms (P>0.05). CONCLUSION: In patients with nonischemic dilated cardiomyopathy, carvedilol leads to a significantly greater improvement in LVEF in patients with the Arg389Arg-β1 adrenergic receptor phenotype.
KW - Beta-adrenergic receptor-blocking drugs
KW - Beta1-adrenergic and beta2-adrenergic receptors
KW - Cardiomyopathy
KW - Carvedilol
KW - Genetic polymorphisms
KW - Heart failure
UR - http://www.scopus.com/inward/record.url?scp=37349022820&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=37349022820&partnerID=8YFLogxK
U2 - 10.1097/FPC.0b013e3282ef7354
DO - 10.1097/FPC.0b013e3282ef7354
M3 - Article
C2 - 18075464
AN - SCOPUS:37349022820
SN - 1744-6872
VL - 17
SP - 941
EP - 949
JO - Pharmacogenetics and Genomics
JF - Pharmacogenetics and Genomics
IS - 11
ER -